(Press-News.org) SAN ANTONIO, Oct. 5, 2023 – Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio (UT Health San Antonio) have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment.
The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of Health that will pave the way for a clinical trial next year for patients with advanced lung cancer. The research is detailed in a new article in Cell Reports, a peer-reviewed scientific journal publishing research papers across a broad range of disciplines within the life sciences.
“For the trial, we will be looking to recruit patients with lung adenocarcinoma, the most common primary lung cancer in the United States, and particularly those with a refractory condition for which treatment hasn’t been effective,” said Josephine A. Taverna, MD, a faculty member in hematology and oncology with the Mays Cancer Center at UT Health San Antonio, and principal investigator of the NCI/NIH grant.
She also is a lead author of the Cell Reports article titled, “AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages,” along with Tim Hui-Ming Huang, PhD, professor and chair of the Department of Molecular Medicine at UT Health San Antonio and deputy director of Mays Cancer Center.
They are joined by a team of clinical investigators at Mays Cancer Center and faculty in the departments of molecular medicine, cardiothoracic surgery, pulmonology, population health sciences and biostatistics at UT Health San Antonio, along with The University of Texas MD Anderson Cancer Center in Houston and industry partners BerGenBio and Sobi.
Tumor-associated macrophages are types of white blood cells that in dysfunctional form are integral to the development of complex tumor microenvironments, or ecosystems, promoting tumor growth, invasion, metastasis and drug resistance. Signaling of these macrophages early on for lung cancer has been elusive.
However, the research by Taverna and her colleagues indicates that certain proteins known as AXL and STAT3 together transmit signals that appear in more advanced stages of lung cancer. This signaling in tumor-associated macrophages is triggered by lung cancer cells and cancer-associated cells.
“These findings suggest the potential application of AXL-STAT3-related markers to quantitatively assess metastatic potential and inform therapeutic strategies in lung cancer,” Taverna said. “It provides a therapeutic rationale for targeting this network.”
The researchers derived their results by conducting single-cell proteomic profiling of 15 lung tumors from 13 patients with lung adenocarcinoma, one patient with squamous cell lung cancer and one patient with pleiomorphic carcinoma. They found predominant and consistent AXL-STAT3 signaling in tumor and other cancer-related cells.
“Our initial observation suggests that concomitantly high AXL/STAT3 signaling in tumor-associated macrophages may contribute to the conditioning of pro-metastatic niches,” Taverna said. “Our experiments in the lab suggest that targeting the AXL-STAT3 pathway can prevent tumor cells from recruiting tumor-associated macrophages and other aggressive host cells into the tumor microenvironment, thereby inhibiting tumor growth and spread.”
UT Health San Antonio is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages
Chia-Nung Hung, Meizhen Chen, Daniel T. DeArmond, Cheryl Hsiang-Ling Chiu, Catherine A. Limboy, Xi Tan, Meena Kusi, Chih-Wei Chou, Li-Ling Lin, Zhao Zhang, Chiou-Miin Wang, Chun-Liang Chen, Kohzoh Mitsuya, Pawel A. Osmulski, Maria E. Gaczynska, Nameer B. Kirma, Ratna K. Vadlamudi, Don L. Gibbons, Steve Warner, Andrew J. Brenner, Daruka Mahadevan, Joel E. Michalek, Tim Hui-Ming Huang, Josephine A. Taverna
First published: Sept. 1, 2023, Cell Reports
Link to the article: https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01078-1
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions, graduate biomedical sciences and public health have graduated more than 42,200 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.
The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit https://cancer.uthscsa.edu.
Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube.
END
Mays Cancer Center at UT Health San Antonio identifies possible markers for early metastatic lung cancer
2023-10-05
ELSE PRESS RELEASES FROM THIS DATE:
WHO director praises London’s ULEZ expansion as politically courageous
2023-10-05
London mayor Sadiq Khan’s efforts to expand the capital’s Ultra Low Emission Zone (ULEZ) as part of a push to reduce air pollution and improve health, is politically courageous and an example for mayors around the world, says the World Health Organization’s environment, climate change and health director, Maria Neira.
In an exclusive interview for The BMJ’s climate issue, Neira says she is tired of listening to politicians speak on climate change as if they didn't have the power to ...
Software can detect hidden and complex emotions in parents
2023-10-05
Researchers have conducted trials using a software capable of detecting intricate details of emotions that remain hidden to the human eye.
The software, which uses an ‘artificial net’ to map key features of the face, can evaluate the intensities of multiple different facial expressions simultaneously.
The University of Bristol and Manchester Metropolitan University team worked with Bristol’s Children of the 90s study participants to see how well computational methods could capture authentic human emotions amidst everyday ...
$2 million grant boosts technological advancements in cutting-edge cell therapy manufacturing facility
2023-10-05
The Keck School of Medicine of USC has received $2 million from the California Institute of Regenerative Medicine (CIRM) to further augment its newly launched cGMP Laboratory, a state-of-the-art facility designed to advance early-stage research into clinically viable cell and gene therapies. To expedite the translation of these therapies from the lab to the clinic, the facility needs advanced technological know-how, streamlined operations and strict protocols for developing and testing these products, all of which ...
Texas Children’s Bariatric Surgery Program receives prestigious national accreditation
2023-10-05
HOUSTON (October 4, 2023) – Texas Children’s Hospital is proud to announce that its Adolescent Bariatric Surgery Program has received national accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).
Texas Children’s Hospital The Woodlands is the only Bariatric Surgery Center in the state of Texas that serves to an adolescent-only patient population with a multidisciplinary clinical staff who is certified to meet the surgical, medical and psychological needs of ...
Two-dimensional compounds can capture carbon from the air
2023-10-05
Some of the thinnest materials known to mankind may provide solutions to scientists in their quest to curb the effects of global warming.
Known as MXene and MBene compounds, these substances are only a few atoms thick, making them two-dimensional. Because of their large surface area, the materials have the potential to absorb carbon dioxide molecules from the atmosphere, which could help reduce the harmful effects of climate change by safely sequestering carbon dioxide.
In a paper published Oct. 4 in the journal Chem, UC Riverside professor Mihri Ozkan and her co-authors explain the potential of MXenes and MBenes in carbon capture technologies.
“In this review, ...
New type of tiny wasp comes with mysterious, cloud-like structures at ends of antennae
2023-10-05
CORVALLIS, Ore. – Fossil researchers have discovered a novel genus and species of tiny wasp with a mysterious, bulbous structure at the end of each antenna.
The female micro-wasp was described from 100-million-year-old Burmese amber in a study led by George Poinar Jr., who holds a courtesy appointment in the Oregon State University College of Science.
Poinar and Fernando Vega, an independent researcher based in Silver Spring, Maryland, have some ideas about the “clouds” on the ...
Tirzepatide is as effective at treating early-onset type 2 diabetes as diabetes diagnosed later in life
2023-10-05
Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.
Tirzepatide belongs to a new class of drugs that mimic the effect of two hormones involved in blood sugar control and appetite suppression, ...
Commonly prescribed antibiotic, antipsychotic and prokinetic drugs are associated with a higher risk of sudden cardiac arrest (SCA) in people with type 2 diabetes, study finds
2023-10-05
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has identified a range of characteristics associated with a higher risk of sudden cardiac arrest in individuals with type 2 diabetes.
These include the some commonly prescribed antibiotic and antipsychotic drugs, prokinetics (drugs used to treat gastrointestinal symptoms such as nausea and vomiting) and low fasting blood sugar.
Sudden cardiac arrest (SCA) is a leading cause of death. ...
Study reveals distinct illness trajectory in the years leading up to type 2 diabetes diagnosis
2023-10-05
New research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Hamburg (2-6 Oct), reveals a marked increase in several common conditions in the years leading up to, and immediately prior to, type 2 diabetes diagnosis, suggesting considerably earlier diagnosis might be possible in some patients.
“These novel insights into the onset and natural progression of type 2 diabetes, suggest an early phase of inflammation-related disease activity long before any clinical diagnosis of type 2 diabetes is made”, says senior author Dr Adrian Heald from Manchester ...
Is lasting remission of type 2 diabetes feasible in the real-world setting?
2023-10-05
At this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.
Professor Roy Taylor of Newcastle University, Newcastle, UK, will be speaking in support of the motion
Professor Taylor will argue that through a series of studies in which people with type 2 diabetes were put on low calorie diets, he has shown that lasting remission of type 2 diabetes is indeed feasible in the real world.
He will begin ...